Westwind Capital Buys 1,211 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Westwind Capital raised its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 2.8% during the 4th quarter, HoldingsChannel reports. The firm owned 44,662 shares of the company’s stock after purchasing an additional 1,211 shares during the quarter. IDEXX Laboratories comprises 4.0% of Westwind Capital’s holdings, making the stock its 11th biggest position. Westwind Capital’s holdings in IDEXX Laboratories were worth $18,465,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently modified their holdings of IDXX. Foundations Investment Advisors LLC boosted its position in shares of IDEXX Laboratories by 10.2% in the second quarter. Foundations Investment Advisors LLC now owns 495 shares of the company’s stock valued at $241,000 after acquiring an additional 46 shares during the period. Private Advisor Group LLC increased its holdings in shares of IDEXX Laboratories by 8.7% during the 2nd quarter. Private Advisor Group LLC now owns 2,287 shares of the company’s stock worth $1,114,000 after purchasing an additional 183 shares during the period. Acadian Asset Management LLC raised its position in shares of IDEXX Laboratories by 125.8% during the second quarter. Acadian Asset Management LLC now owns 9,527 shares of the company’s stock valued at $4,637,000 after buying an additional 5,308 shares during the last quarter. Caprock Group LLC lifted its stake in shares of IDEXX Laboratories by 33.6% in the second quarter. Caprock Group LLC now owns 2,853 shares of the company’s stock valued at $1,390,000 after buying an additional 717 shares during the period. Finally, Ballentine Partners LLC grew its position in IDEXX Laboratories by 7.9% during the second quarter. Ballentine Partners LLC now owns 1,282 shares of the company’s stock worth $625,000 after buying an additional 94 shares in the last quarter. Institutional investors own 87.84% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages recently commented on IDXX. Barclays reduced their target price on IDEXX Laboratories from $570.00 to $481.00 and set an “overweight” rating for the company in a research report on Monday, November 4th. Leerink Partners assumed coverage on shares of IDEXX Laboratories in a research note on Monday, December 2nd. They issued an “outperform” rating and a $500.00 target price on the stock. StockNews.com raised IDEXX Laboratories from a “hold” rating to a “buy” rating in a report on Thursday, November 28th. JPMorgan Chase & Co. dropped their target price on IDEXX Laboratories from $630.00 to $575.00 and set an “overweight” rating for the company in a report on Friday, October 11th. Finally, Piper Sandler reaffirmed a “neutral” rating and issued a $435.00 price target (down previously from $520.00) on shares of IDEXX Laboratories in a research note on Monday, November 4th. Two investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $539.63.

Insider Buying and Selling

In other news, Director Sophie V. Vandebroek sold 344 shares of the firm’s stock in a transaction on Wednesday, November 27th. The stock was sold at an average price of $420.44, for a total value of $144,631.36. Following the transaction, the director now directly owns 905 shares in the company, valued at $380,498.20. This trade represents a 27.54 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 2.11% of the company’s stock.

IDEXX Laboratories Price Performance

NASDAQ:IDXX traded down $2.99 during mid-day trading on Tuesday, reaching $426.17. 342,438 shares of the company were exchanged, compared to its average volume of 412,638. The company has a quick ratio of 1.03, a current ratio of 1.42 and a debt-to-equity ratio of 0.32. The stock has a market cap of $34.90 billion, a PE ratio of 41.10, a PEG ratio of 3.94 and a beta of 1.36. IDEXX Laboratories, Inc. has a 12 month low of $398.50 and a 12 month high of $583.39. The company has a fifty day moving average of $424.02 and a 200 day moving average of $461.79.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings data on Thursday, October 31st. The company reported $2.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.69 by $0.11. The firm had revenue of $975.50 million for the quarter, compared to the consensus estimate of $980.32 million. IDEXX Laboratories had a return on equity of 55.42% and a net margin of 22.53%. The business’s revenue for the quarter was up 6.6% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.53 EPS. On average, research analysts anticipate that IDEXX Laboratories, Inc. will post 10.44 EPS for the current fiscal year.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.